FDA Approves Stelara for Pediatric Crohn’s Disease
FDA DecisionapprovedStelaraPositive
AI Analysis
Summary
The FDA approved Stelara (ustekinumab) for treating moderately to severely active Crohn's disease in patients ages 2 and older on April 15, 2026. This represents an expansion of the drug's labeled indications to the pediatric population.
Outcome Details
FDA approved Stelara for pediatric Crohn's disease in patients 2 years and older
Importance:8/10
Sentiment:
0.90
FDA approvalpediatric indicationCrohn's diseaseStelaraustekinumab
Read the original article
Published by Drugs.com New Drug Approvals on April 15, 2026 2:04 AM